19
Participants
Start Date
May 31, 2007
Primary Completion Date
October 31, 2012
Study Completion Date
March 31, 2013
Sorafenib
Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
Princess Margaret Hospital, University Health Network, Toronto
Collaborators (1)
Bayer
INDUSTRY
University Health Network, Toronto
OTHER